ADHD → Late-Life Cognitive Impairment / Energy-Deficit Mechanism
1 Bauer-Negrini et al. 2026 — ADHD and Late-Life Cognitive Impairment
Full Citation:: Bauer-Negrini G, Leffa DT, Ferreira PCL, et al. Attention-Deficit/Hyperactivity Disorder and Late-Life Cognitive Impairment. JAMA Psychiatry. 2026. Published online 2026-10-07. (Bauer-Negrini et al. 2026) DOI:: 10.1001/jamapsychiatry.2026.3165 PMID:: 42842281 Article Type:: Retrospective cohort (EHR + polygenic risk score) Key Findings::
- All of Us cohort (n=187,341, ≥50 y, mean follow-up 10.26 y): ADHD (n=3,026; 1.6%) → incident MCI/dementia HR 4.60 (95% CI 3.99–5.29, P<.001)
- Attenuated but persistent after somatic comorbidity (4.04), neuropsychiatric comorbidity (3.19), full adjustment incl. education/utilization (3.08); 1:2 matched HR 2.26
- ADHD PRS highest-vs-lowest quintile HR 1.35 (1.25–1.46)
- Comorbid ADHD among incident-cases: worse mental health OR 1.69, QoL OR 1.66, social satisfaction OR 2.39, +20% healthcare utilization
- Reverse-causation lag ≥9 y → non-significant (HR 1.28, P=.07)Conclusion:: Convergent clinical + genetic evidence that ADHD markedly raises late-life cognitive-impairment risk. Limitations:: Observational residual confounding; EHR ascertainment; long dementia prodrome (reverse causation not fully excluded). ME/CFS Relevance:: Driving paper for the ADHD→dementia link that frames the shared neuronal energy-deficit mechanism. Certainty Assessment::
- *Quality:* High (JAMA Psychiatry; large diverse cohort)
- *Sample:* n=187,341
- *Replication:* Consistent with Tzeng 2019, Dobrosavljevic 2021, Levine 2023
- *Score:* 0.85 (raw; population 0.75 → discounted 0.64)2 Tzeng et al. 2019 — Dementia Risk in Adults With ADHD (Taiwan)
Full Citation:: Tzeng NS, Chung CH, Lin FH, et al. Risk of Dementia in Adults With ADHD: A Nationwide, Population-Based Cohort Study in Taiwan. Journal of Attention Disorders. 2019;23(9):995–1006. (Tzeng et al. 2019) DOI:: 10.1177/1087054717714057 PMID:: 28629260 Article Type:: Nationwide register cohort Key Findings::
- Taiwan National Health Insurance; ADHD vs 1:3 matched controls; dementia 5.48% vs 4.0%
- Adjusted HR 4.008 (95% CI 2.526–6.361)Conclusion:: Earliest large national demonstration of ADHD→dementia association; supports the driving paper. Limitations:: EHR diagnosis; no stimulant/lifetime treatment data; limited covariate set. ME/CFS Relevance:: Independent Asian-cohort replication of the direct association. Certainty Assessment::
- *Quality:* Medium (national data, modest dementia events)
- *Sample:* national register
- *Replication:* Replicated by later cohorts
- *Score:* 0.60 (raw; population 0.75 → discounted 0.45)3 Dobrosavljevic et al. 2021 — ADHD as Risk Factor for Dementia and MCI (Sweden)
Full Citation:: Dobrosavljevic M, Zhang L, Garcia-Argibay M, et al. Attention-deficit/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: a population-based register study. European Psychiatry. 2021;65(1):1–19. (Dobrosavljevic et al. 2021) DOI:: 10.1192/j.eurpsy.2021.2261 PMID:: 34924079 Article Type:: Population register cohort (n=3,591,689) Key Findings::
- ADHD → dementia HR 2.92 (2.40–3.57); MCI HR 6.21 (5.25–7.35)
- Psychiatric-comorbidity adjustment attenuated to dementia HR 1.62 (1.32–1.98), MCI 2.54 (2.14–3.01)
- Metabolic disorders, sleep, head injury, education had limited impact; stronger in menConclusion:: ADHD raises dementia/MCI risk but psychiatric comorbidity is a major confounder. Limitations:: Register ICD codes; no treatment data; residual confounding. ME/CFS Relevance:: Quantifies the psychiatric-comorbidity confound that must be weighed in cross-disease reasoning. Certainty Assessment::
- *Quality:* High (nearly 3.6M)
- *Sample:* n=3,591,689
- *Replication:* Consistent
- *Score:* 0.80 (raw; population 0.75 → discounted 0.60)4 Levine et al. 2023 — Adult ADHD and the Risk of Dementia
Full Citation:: Levine SZ, Rotstein A, Kodesh A, et al. Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia. JAMA Network Open. 2023;6(10):e2338088. (Levine et al. 2023) DOI:: 10.1001/jamanetworkopen.2023.38088 PMID:: 37847497 Article Type:: Prospective national cohort (n=109,218) Key Findings::
- Adult ADHD (n=730) → unadjusted dementia HR 3.62 (2.92–4.49); 18-confounder IPW-adjusted HR 2.77 (2.11–3.63)
- No clear dementia risk increase among psychostimulant-treated adults; mild reverse causationConclusion:: Replicates the association and supplies the stimulant-confounding null. Limitations:: EHR diagnoses; 0.7% ADHD prevalence (under-ascertainment); treatment exposure imprecise. ME/CFS Relevance:: Key source for the stimulant (harm/confounder) angle — stimulants do NOT appear to drive the dementia signal. Certainty Assessment::
- *Quality:* High (JAMA Netw Open; 18-confounder adjustment)
- *Sample:* n=109,218
- *Replication:* Consistent
- *Score:* 0.80 (raw; population 0.75 → discounted 0.60)5 Golimstok et al. 2024 — ADHD, Lewy Body Disease, and Cognitive Impairment
Full Citation:: Golimstok Á, Basalo MJG, Majul M, et al. Adult Attention Deficit-Hyperactivity Disorder is associated with Lewy Body Disease and Cognitive Impairment: A prospective cohort study with 15-year follow-up. American Journal of Geriatric Psychiatry. 2024;32(9):1063–1077. (Golimstok et al. 2024) DOI:: 10.1016/j.jagp.2024.04.005 PMID:: 38697886 Article Type:: Prospective 15-year cohort (n=161 ADHD, n=109 control) Key Findings::
- Dementia: 27 ADHD vs 4 control; DLB predominant (19/20 DLB in ADHD group)
- Adjusted HR dementia 3.33 (1.09–10.17); LBD HR 54.54 (7.48–397.50); non-amnestic MCI 67.1% of ADHDConclusion:: ADHD maps to a Lewy-body/synuclein (dopaminergic) trajectory, not amyloid-AD. Limitations:: Small sample; clinic-recruited; wide CIs. ME/CFS Relevance:: Supports a catecholaminergic/energy mechanism over an amyloid-centric one — more consistent with the energy-deficit hypothesis. Certainty Assessment::
- *Quality:* Medium (small but long follow-up)
- *Sample:* n=270
- *Replication:* Partially replicated
- *Score:* 0.62 (raw; population 0.75 → discounted 0.47)6 Du Rietz et al. 2021 — ADHD and Physical Conditions in Adulthood (Sweden)
Full Citation:: Du Rietz E, Brikell I, Butwicka A, et al. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. The Lancet Psychiatry. 2021;8(9):774–783. (Du Rietz et al. 2021) DOI:: 10.1016/S2215-0366(21)00171-1 PMID:: 34242595 Article Type:: Genetically informed register study (n=4,789,799) Key Findings::
- ADHD associated with multiple physical conditions (nervous-system, cardiovascular, metabolic) across adulthood
- Associations partly explained by shared genetic/familial factorsConclusion:: Establishes the vascular/cardiometabolic burden channel (competing mechanism) linking ADHD to later dementia. Limitations:: Register diagnoses; sibling design assumptions. ME/CFS Relevance:: Competing-mechanism evidence — ADHD’s elevated cardiometabolic load is an alternative (non-energy-specific) path to dementia. Certainty Assessment::
- *Quality:* High (large, genetically informed)
- *Sample:* n=4,789,799
- *Replication:* Consistent with ADHD-comorbidity literature
- *Score:* 0.78 (raw; population 0.75 → discounted 0.59)7 Rast et al. 2026 — Neurodevelopmental Conditions, ADRD, and Parkinson’s Disease
Full Citation:: Rast JE, Rosso AL, James BD, et al. Association of neurodevelopmental conditions with Alzheimer’s disease and related dementias and Parkinson’s disease. The Journals of Gerontology. Series A. 2026;81(4):glaf281. (Rast et al. 2026) DOI:: 10.1093/gerona/glaf281 PMID:: 41429566 Article Type:: Case-control (All of Us, n≈600,000) Key Findings::
- NDC (ADHD + autism) more prevalent in ADRD (7.8% vs 2.4%) and PD (4.5% vs 1.8%) cases
- Adjusted OR ADRD 2.68 (2.40–2.99); PD 2.09 (1.66–2.59)Conclusion:: Extends ADHD-only finding to autism and other neurodevelopmental conditions. Limitations:: Case-control; cross-sectional NDC ascertainment. Shares All of Us cohort with Bauer-Negrini 2026 (cohort overlap). ME/CFS Relevance:: Brings autism into the neurodevelopmental→neurodegeneration link, strengthening the ADHD/ASD energy-deficit parallel. Certainty Assessment::
- *Quality:* Medium (case-control; overlaps driving cohort)
- *Sample:* n≈600,000
- *Replication:* Consistent
- *Score:* 0.72 (raw; population 0.75 → discounted 0.54)8 Leffa et al. 2023 — ADHD Genetic Risk Predicts Cognitive Decline and AD Pathophysiology
Full Citation:: Leffa DT, Ferrari-Souza JP, Bellaver B, et al. Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults. Molecular Psychiatry. 2023;28(3):1248–1255. (Leffa et al. 2023) DOI:: 10.1038/s41380-022-01867-2 PMID:: 36476732 Article Type:: Prospective genetic cohort (ADNI) Key Findings::
- ADHD PRS predicted longitudinal cognitive decline and development of AD pathophysiology (amyloid/tau) in cognitively unimpaired older adultsConclusion:: Genetic (not diagnostic) evidence bypasses EHR ascertainment and reverse causation; supports shared liability. Limitations:: ADNI sample ancestry homogeneity; PRS pleiotropy; same Pittsburgh group as driving paper (no cohort overlap). ME/CFS Relevance:: Genetic arm of the ADHD→neurodegeneration link, consistent with a shared underlying liability rather than care-seeking confound. Certainty Assessment::
- *Quality:* High (ADNI; genetic)
- *Sample:* ADNI cohort
- *Replication:* Independent PRS literature emerging
- *Score:* 0.75 (raw; population 0.75 → discounted 0.56)9 Becker et al. 2022 — ADHD and Neurodegenerative Risk: A Critical Examination
Full Citation:: Becker S, Sharma MJ, Callahan BL. ADHD and Neurodegenerative Disease Risk: A Critical Examination of the Evidence. Frontiers in Aging Neuroscience. 2022;13:826213. (Becker, Sharma, and Callahan 2022) DOI:: 10.3389/fnagi.2021.826213 PMID:: 35145394 Article Type:: Critical narrative review Key Findings::
- Appraises the first 8 ADHD→neurodegeneration studies (Lewy-body risk up to 5-fold)
- Flags EHR diagnostic inaccuracy, ADHD-status measurement bias, cohort representativeness, bidirectional confounding (under- and over-estimation)Conclusion:: Principal methodological-caution (null-tempering) source; risk estimates may be under- or over-stated. Limitations:: Review; no new data. ME/CFS Relevance:: Discipline against over-reading the direct ADHD→dementia association. Certainty Assessment::
- *Quality:* Medium (critical review)
- *Sample:* n/a (8 studies reviewed)
- *Replication:* n/a
- *Score:* 0.58 (raw; population 0.75 → discounted 0.44)10 Becker et al. 2023 — Neurodegenerative Disease Risk in Adults With ADHD: Systematic Review
Full Citation:: Becker S, Chowdhury M, Tavilsup P, Seitz D, Callahan BL. Risk of neurodegenerative disease or dementia in adults with attention-deficit/hyperactivity disorder: a systematic review. Frontiers in Psychiatry. 2023;14:1158546. (Becker et al. 2023) DOI:: 10.3389/fpsyt.2023.1158546 PMID:: 37663597 Article Type:: Systematic review (PROSPERO CRD42022348976) Key Findings::
- 2,137 screened; 7 studies (5 cohort, 2 case-control) met criteria
- Heterogeneous covariates precluded meta-analysis; narrative synthesis
- Evidence for a link exists but magnitude of a direct effect undetermined; mechanism unresolvedConclusion:: Honest “limited/undetermined magnitude” synthesis of the ADHD→dementia literature. Limitations:: Few studies; heterogeneity; no meta-analysis. ME/CFS Relevance:: The null/uncertain-magnitude anchor for the direct association. Certainty Assessment::
- *Quality:* Medium (systematic review, few primary studies)
- *Sample:* 7 studies
- *Replication:* n/a
- *Score:* 0.70 (raw; population 0.75 → discounted 0.53)11 Fluegge & Fluegge 2018 — Antecedent ADHD, Dementia, and Metabolic Dysregulation
Full Citation:: Fluegge K, Fluegge K. Antecedent ADHD, dementia, and metabolic dysregulation: A U.S. based cohort analysis. Neurochemistry International. 2018;112:255–258. (Fluegge and Fluegge 2018) DOI:: 10.1016/j.neuint.2017.08.005 PMID:: 28811268 Article Type:: Hospitalization cohort (HCUP) Key Findings::
- 10-y lagged severe ADHD raised LBD hospitalization (IRR 1.21, 1.08–1.35) and AD discharge (IRR 1.15, 1.05–1.27)
- Controlling for diabetes removed the ADHD–AD associationConclusion:: Metabolic/energy (glycemic) dysregulation mediates part of the ADHD→dementia link. Limitations:: Administrative data; severe-phenotype proxy; small effect sizes. ME/CFS Relevance:: Independent support for an energy/metabolic-mediation channel — foreshadows the energy-deficit mechanism. Certainty Assessment::
- *Quality:* Low-medium (administrative, proxy exposure)
- *Sample:* HCUP discharge data
- *Replication:* Not independently replicated
- *Score:* 0.52 (raw; population 0.75 → discounted 0.39)12 Golimstok & Berrios 2025 — Adult ADHD as Dementia Risk Factor: Mechanisms and Stimulant Role
Full Citation:: Golimstok A, Berrios W. Adult ADHD as a risk factor for dementia: integrating longitudinal evidence, mechanistic insights, and the role of stimulant treatment. Frontiers in Dementia. 2025;4:1735357. (Golimstok and Berrios 2025) DOI:: 10.3389/frdem.2025.1735357 PMID:: 41477452 Article Type:: Narrative review Key Findings::
- Convergent mechanisms: dopaminergic dysregulation, possible Wnt/mTOR alterations, oxidative stress, chronic neuroinflammation; comorbidity/lifestyle/cognitive reserve amplify vulnerability
- Preliminary data suggest stimulants may attenuate dementia risk (dopaminergic tone/plasticity/oxidative stress); RCTs lackingConclusion:: ADHD is a developmental, potentially modifiable dementia risk factor; stimulant role unresolved. Limitations:: Narrative review; stimulant-protective data preliminary. ME/CFS Relevance:: Mechanism + stimulant-direction synthesis for the competing-mechanism angle. Certainty Assessment::
- *Quality:* Medium (narrative review)
- *Sample:* n/a
- *Replication:* n/a
- *Score:* 0.58 (raw; population 0.75 → discounted 0.44)13 Cunnane et al. 2011 — Brain Fuel Metabolism, Aging, and Alzheimer’s Disease
Full Citation:: Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition. 2011;27(1):3–20. (Cunnane et al. 2011) DOI:: 10.1016/j.nut.2010.07.021 PMID:: 21035308 Article Type:: Review (brain energy metabolism) Key Findings::
- Lower brain glucose metabolism precedes clinical cognitive decline in at-risk AD groups (APOE4 carriers, maternal AD family history)
- Candidate defects: brain glucose transport, disrupted glycolysis, impaired mitochondrial function
- Self-reinforcing vicious cycle (AD reduces synaptic energy demand, further lowering metabolism)Conclusion:: Brain hypometabolism may precede and contribute to the neuropathologic cascade of AD. Limitations:: Review; causal ordering (upstream vs downstream) unresolved. ME/CFS Relevance:: Anchor for the “cerebral energy deficit → neurodegeneration” link of the energy-deficit hypothesis. Certainty Assessment::
- *Quality:* High (authoritative review)
- *Sample:* n/a
- *Replication:* Extensively corroborated by later FDG-PET literature
- *Score:* 0.72 (raw; population 0.75 → discounted 0.54)14 Swerdlow et al. 2014 — The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Full Citation:: Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2014;1842(8):1219–1231. (Swerdlow, Burns, and Khan 2014) DOI:: 10.1016/j.bbadis.2013.09.010 PMID:: 24071439 Article Type:: Hypothesis/review (mitochondrial bioenergetics) Key Findings::
- Mitochondrial cascade: inherited baseline function + environmental change-rates drive sporadic AD chronology
- Mitochondrial function gates APP processing / Aβ accumulation (amyloid cascade is downstream of bioenergetic failure)Conclusion:: Bioenergetic failure is upstream of amyloid pathology in sporadic late-onset AD. Limitations:: Hypothesis; direct causal demonstration incomplete. ME/CFS Relevance:: Theoretical anchor for mitochondrial/bioenergetic failure as the shared neurodegeneration mechanism. Certainty Assessment::
- *Quality:* High (leading hypothesis)
- *Sample:* n/a
- *Replication:* Supported by emerging biomarker/animal work
- *Score:* 0.70 (raw; population 0.75 → discounted 0.53)15 Mosconi 2013 — Glucose Metabolism in Normal Aging and Alzheimer’s Disease
Full Citation:: Mosconi L. Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clinical and Translational Imaging. 2013;1(4):217–233. (Mosconi 2013) DOI:: 10.1007/s40336-013-0026-y PMID:: 24409422 Article Type:: Review (FDG-PET) Key Findings::
- FDG-PET metabolic reductions occur decades before AD symptom onset (upstream event)
- Hypometabolism present in at-risk individuals (maternal AD family history), in posterior cingulate/parietal/temporal association cortexConclusion:: FDG-PET hypometabolism is the measurable “cerebral energy deficit” signature of preclinical AD. Limitations:: Review; methodological variability across PET studies. ME/CFS Relevance:: Parallel to ME/CFS cerebral hypometabolism findings (already in corpus) — supports a shared imaging phenotype of cerebral energy deficit. Certainty Assessment::
- *Quality:* Medium (review; PET methodology variance)
- *Sample:* n/a
- *Replication:* Well-replicated pattern
- *Score:* 0.60 (raw; population 0.75 → discounted 0.45)